BeiGene, Ltd.

NasdaqGS:BGNE Stock Report

Market Cap: US$18.8b

BeiGene Future Growth

Future criteria checks 4/6

BeiGene is forecast to grow earnings and revenue by 73.3% and 19.2% per annum respectively. EPS is expected to grow by 75.7% per annum. Return on equity is forecast to be 15.7% in 3 years.

Key information

73.3%

Earnings growth rate

75.7%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate19.2%
Future return on equity15.7%
Analyst coverage

Good

Last updated18 Dec 2024

Recent future growth updates

Recent updates

BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US

Dec 01

BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion

Nov 06

BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat

Aug 22

Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts

Aug 14
Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts

BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth

Aug 09
BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

Jun 21

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

May 30
We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

Apr 21
Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

Mar 08

BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Jan 31
BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Earnings and Revenue Growth Forecasts

NasdaqGS:BGNE - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202641,0932,8322,3965,84025
12/31/202534,078-525-1,43197529
12/31/202427,083-4,294-5,222-2,43429
9/30/202423,508-5,993-8,599-4,559N/A
6/30/202422,504-3,806-9,856-5,116N/A
3/31/202419,948-5,664-11,307-6,515N/A
12/31/202317,452-6,258-12,448-8,215N/A
9/30/202315,649-7,128-12,061-7,723N/A
6/30/202313,139-12,570-16,568-12,609N/A
3/31/202310,694-13,166-15,784-12,525N/A
12/31/20229,766-13,820-13,558-10,322N/A
9/30/20228,892-15,291-15,252-11,997N/A
6/30/20227,160-13,600-13,507-10,855N/A
3/31/20225,561-12,424-12,963-10,528N/A
12/31/20217,475-9,264-10,254-8,253N/A
9/30/20216,851-8,641-8,605-7,243N/A
6/30/20216,115-8,569-7,704-6,288N/A
3/31/20215,653-7,645-6,748-5,350N/A
12/31/20202,016-10,608-9,860-8,378N/A
9/30/20201,804-10,268-9,683-8,272N/A
6/30/20201,588-9,852-9,189-8,034N/A
3/31/20202,850-8,108-7,738-6,518N/A
12/31/20192,982-6,605-6,328-5,224N/A
9/30/20193,073-5,923-6,259-4,838N/A
6/30/20192,980-4,570-5,129-3,737N/A
3/31/20191,634-4,945-5,283-4,129N/A
12/31/20181,363-4,635-4,736-3,767N/A
9/30/20181,083-3,468-2,364-1,786N/A
6/30/20182,143-1,611N/A-803N/A
3/31/20181,700-923N/A-352N/A
12/31/20171,551-606N/A83N/A
9/30/20171,465-209N/A-713N/A
6/30/2017N/A-1,249N/A-936N/A
3/31/20173-1,018N/A-726N/A
12/31/20167-828N/A-622N/A
9/30/201638-726N/A-534N/A
6/30/201647-581N/A-437N/A
3/31/201652-445N/A-361N/A
12/31/201557-371N/A-259N/A
9/30/201535-214N/A-214N/A
6/30/201566-182N/A-121N/A
3/31/201573-162N/A-69N/A
12/31/201481-113N/A-54N/A
12/31/201367-45N/A25N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BGNE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: BGNE is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BGNE is expected to become profitable in the next 3 years.

Revenue vs Market: BGNE's revenue (19.2% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: BGNE's revenue (19.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BGNE's Return on Equity is forecast to be low in 3 years time (15.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 01:58
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BeiGene, Ltd. is covered by 57 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Michael MengBOCI Research Ltd.
Yonglin YanBOCI Research Ltd.